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Background: Combination of fluoropyrimidines and a platinum derivative are currently standards for systemic
chemotherapy in advanced adenocarcinoma of the stomach and gastroesophageal junction (GEJ). Nevertheless,
individual likelihood for response to these therapeutic regimes remains uncertain. Even more, no predictive markers are
available to determine which patients may benefit more from oxaliplatin versus cisplatin or vice versa. The new invasion
and stem cell markers VEGFR-3 and CXCR4 have been linked prognostically with more aggressive esophagogastric
cancer types. Thus, we aimed to assess correlations of VEGFR-3 and CXCR4 expression levels with clinical outcome in a
randomized phase III study of patients with oxaliplatin/leucovorin/5-FU (FLO) versus cisplatin/leucovorin/5-FU (FLP).
Methods: The patients data examined in this study (n = 72) were from the collective of the FLO vs. FLP phase III AIO
trial. Tumour tissues were stained via immunohistochemistry for VEGFR-3 and CXCR4 expression and results were
evaluated by two independent, blinded investigators.
Outcome parameter: Survival analysis was calculated for patients receiving FLO vs. FLP in relation to VEGFR-3 and CXCR4
expression.
Results: 54% and 36% of the examined tumour tissues showed strong positive expression of VEGFR-3 and CXCR4
respectively. No superiority of each regime was detected in terms of overall survival (OS) in the whole population.
Patients with strong expression of CXCR4 on their tumour tissues profited more in terms of OS under the treatment of
FLP (mOS: 28 vs 15 months, p = 0.05 respectively). Patients with negative VEGFR-3 and CXCR4 expression had a trend
to live longer when FLO regime was applied (mOS: 22 vs. 9 months, p = 0.099 and 20 vs. 10 months, p = 0.073
respectively). In an exploratory analysis of patients older than 60 years at diagnosis, we observed a significant benefit in
overall survival for VEGFR-3 and CXCR4-positive patients when treated with FLP (p = 0.002, p = 0.021 respectively).
Conclusions: CXCR4 positive patients profited in terms of OS from FLP, whereas FLO proved to be more effective in
CXCR4 and VEGFR-3 negative patients. Our results suggest, despite the limited size of the study, a predictive value of
these biomarkers concerning chemotherapy with FLP or FLO in advanced esophagogastric cancer.
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Adenocarcinoma of the stomach and the gastroesophageal
junction (GEJ) is one of the most common and lethal
malignancies with approximately 990,000 new cases and
738,000 deaths per year worldwide [1]. Most gastric can-
cers are unfortunately diagnosed at an advanced stage, so
that even after a potential curative gastrectomy relapse
rates remain at levels of between 40% and 60% [2].
Systemic chemotherapy is nowadays the gold standard
for the palliative treatment of patients with advanced or
metastatic cancer of the stomach or GEJ. The combi-
nation of fluoropyrimidine and platinum is widely con-
sidered to be the treatment of choice in advanced gastric
cancers having shown a benefit in overall survival (OS)
and progression free survival (PFS) in different studies
[3-5]. Nevertheless, the focus of recent and current stu-
dies remains the identification of a superior treatment
combination while minimizing toxicity.
To the best of our knowledge, there are two phase III
studies that deal with the effect and toxicity of oxaliplatin
compared with cisplatin in the treatment of metastatic
esophagogastric cancer [6,7]. Data from the REAL-2 trial
[6] showed no inferiority of oxaliplatin versus cisplatin or
of capecitabine versus 5-FU for treatment in this category
of patients. Moreover in a post-hoc subgroup analysis
oxaliplatin proved to be more effective than cisplatin in
patients >65 years [7].
In the search of new biomarkers for advanced esophago-
gastric carcinoma, VEGFR-3 and CXCR4 have recently
become the focus of research [8-17]. VEGFR-3 has been
associated with lymphangiogenesis, invasion and meta-
stasis of gastric cancer [9,10,18-21] whilst CXCR4 is as-
sociated with stimulation of angiogenesis, lymph node
metastasis and peritoneal carcinomatosis [16,22-26]. Ne-
vertheless, their role as predictive markers or as potential
therapeutic targets in advanced esophagogastric cancer
remains unclear. Despite the encouraging results of the
addition of bevacizumab in phase II trials in metastatic
and loco regional esophagogastric cancer [27,28], a signifi-
cant benefit in terms of OS was not observed in the phase
III AVAGAST trial [29]. Furthermore, there are to date no
comparative studies that focus on a correlation of VEGFR-3
and CXCR4 with the clinical outcome using different
therapeutic regimes in patients with locally advanced or
metastatic adenocarcinoma of the stomach or GEJ.
The aim of this study was to investigate whether
VEGFR-3 and CXCR4 could serve as molecular patterns
for personalisation of standard chemotherapy in patients
with advanced esophagogastric cancer. We therefore
examined and compared the effect of combined che-
motherapy with oxaliplatin/leucovorin/5-FU (FLO) versus
cisplatin/leucovorin/5-FU (FLP) in patients with advanced
esophagogastric cancer in relation to tumour VEGFR-3
and CXCR4 expression.Methods
Patients
The patient data examined in this study (n = 72) ori-
ginate from the collective of the FLO vs. FLP Phase III
trial of the AIO. A comparison of the main disease cha-
racteristics between patients in our study and the overall
trial population is shown in Additional file 1. Patients
were recruited in 31 German and one Swiss centre in a
time period of 3 years. Eligibility criteria were histo-
logical confirmation of locally advanced or metastatic
adenocarcinoma of the stomach or GEJ. Patients had to
be over 18 years old, have not received any prior pallia-
tive chemotherapy, have not suffered from another type
of cancer in the previous five years and have a creatinine
clearance > 50 ml/min and adequate bone marrow func-
tion. Patients gave written informed consent according
to the Helsinki protocol before entering the study, which
was approved by the ethics committees of the partici-
pating institutions and the Federal Institute for Drugs
and Medical Devices (Ref. Nr: 4020513).Treatment
The participants were randomized into two treatment
arms. The FLO-group received infusional oxaliplatin
85 mg/m2 and leucovorin 200 mg/m2 over 2 hours every
2 weeks, followed by an infusion of 5-FU 2600 mg/m2
over 24 hours. Patients in the FLP therapy arm received
cisplatin 50 mg/m2 every 2 weeks, combined with the
weekly infusion of leucovorin 200 mg/m2 over 2 hours
and FU 2000 mg/m2 over 24 hours. After 6 weeks, the
FLP-treatment was followed by a 2-week rest period.Immunohistochemistry
The expression of VEGFR-3 and CXCR4 was analyzed by
immunohistochemistry (IHC). Paraffin-embedded tissue
samples were obtained from 70 patients for CXCR4 and
69 for VEGFR-3, due to limited availability of material.
The nature of the collected material was mainly tumour
resections.
Three micrometer thick tissue sections were cut and
mounted on super frost slides. These were deparaffinized,
rehydrated and peroxidase blocked (3% H2O2 in metha-
nol, 30 min). After blocking of nonspecific protein binding
sites by using fresh frozen plasma (30 min) slides were in-
cubated with the respective primary antibody VEGFR-3
(sc 321, Santa Cruz Biotechnology, UK, 1:200, 2 h) and
CXCR4 (CIO115, Capralogics, USA, 1:300, 1.5 h) at room
temperature, as described before [30-32]. Incubation
with secondary antibody (anti-rabbit–mouse–goat anti-
body) was followed by incubation with streptavidin–POD
(DAKO, Germany, each 15 min). Specific antibody binding
was visualized using DAB solution (DAKO, Germany) and
the tissues were counterstained by hemalaun solution
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specimens were washed in distilled water or DPBS.
Evaluation of staining was performed by two inde-
pendent, blinded pathologists.Statistical analysis
The staining was evaluated by intensity (no staining 0, weak
1, moderate 2, and strong 3) and the extent of the stained
tumour area (0% 0, <25% 1, 25-50% 2, 50-75% 3, > 75% 4).
These two classifications were added together and divided
into the categories negative and positive. Up to a total of
5, staining was scored as negative, from 6 or more it was
considered clearly positive. All statistical analyses were
done by using MedCalc software 2013 in close cooper-
ation with the IMBEI. The survival analysis was performed
by using the Kaplan-Meier method and the log rank test.
To investigate the association between the results of im-
munohistochemistry obtained for VEGFR-3 and CXCR4
and clinical-pathological parameters, univariate statistical
analysis were performed using Pearson's Chi-2 test or
Fisher's exact test. p values < 0.05 were considered to indi-
cate significant differences.Results
Patients characteristics
The average age of patients was 59.8 years and ranged
from 33 to 84 years, two thirds of the patients were male.
There were no major differences concerning the main dis-
ease characteristics in comparison to the overall phase III
trial, see Additional file 1. In the statistical analysis of
VEGF receptor 3 (VEGFR-3), a total of 69 tumour spe-
cimens were included. The cut-off for positive VEGFR-3
expression was drawn at a value of 6, which was true for
39 specimens (54%). 36 patients were treated with FLO,
33 patients received FLP (Table 1). In the statistical ana-
lysis of CXCR4, tissue samples from 70 patients were in-
cluded. 37 of these patients received the FLO regimen, 33
were treated with FLP. The cut-off for a positive detection
was set at 6 as sum of the scores for proportion and inten-
sity of staining (Figure 1). In 26 (36%) of all tissue samples,
a strong CXCR4 expression could be detected.
There was an equal distribution of the patients in
regards of treatment and positivity of markers (Table 2).
Location of the primary and age showed no statistical
significant changes within all groups (Table 1).General statistical analysis
In terms of efficacy, no difference in the response to
the treatment regimens FLO and FLP could be detected
(p = 0.839). Furthermore, there was no significant dif-
ference in survival between VEGFR-3 positive and nega-
tive patients or for CXCR4 expression (data not shown).Results for the VEGF receptor 3
The response to either therapy regimen strongly depended
on the expression status of VEGFR-3. Patients with a
negative VEGFR-3 state significantly benefited from treat-
ment with FLO in survival over 18 months (p = 0.026). A
strong trend in favour of the FLO-therapy was detected
(Figure 2A, p = 0.099), in terms of 5-year survival. The
median survival for VEGFR-3 negative patients was
22 months in FLO, compared to 9 months in the FLP arm
and was statistically significant. Patients with positive
VEGFR-3 status had a median survival benefit of 5 months
under FLP treatment (21 months under FLP vs. 16 months
under FLO). In the 5-year survival, a trend in favour of
the FLP-therapy group was found for patients with strong
expression of VEGFR-3 (Figure 2B, p = 0.227).Results for the CXC receptor 4
The CXCR4 expression in tumour tissues showed a strong
impact on survival in both treatment groups FLO and
FLP. While CXCR4 negative patients showed a trend to-
wards treatment benefit with FLO (Figure 3A, p = 0.073),
patients with strong CXCR expression survived longer
under FLP treatment (Figure 3B, p = 0.05). The median
survival of patients with negative CXCR4-status was a
statistic relevant 10 months longer under FLO than FLP
(20 vs. 10 months), while strong CXCR4 expression was
associated with a statistically significant median survival
benefit of 13 months for FLP compared with FLO (28 vs.
15 months, p = 0.05).Patients older than 60 years
At this part of our study we performed an exploratory
analysis examining whether VEGFR-3 and CXCR4 show
the same predictive value for older patients.
In the post-hoc subgroup of patients older than 60 years
at diagnosis, we found a significant benefit in overall sur-
vival for VEGFR-3 and CXCR4 positive patients when
treated with FLP (Figure 4A and B, p = 0.002, p = 0.021 re-
spectively). No patient of this subgroup with negative
VEGFR-3 expression status survived the first year after
diagnosis of gastric cancer. However, similar findings were
not observed when older patients with weak tumour ex-
pression of VEGFR-3 and CXCR4 were treated with FLO
(data not shown).Combination of the results for VEGFR-3 and CXCR4
Patients with a strong expression of VEGFR-3 and CXCR4
benefited in overall survival from the treatment with the
cisplatin-containing FLP scheme (Figure 5A, p = 0.126). In
contrast, patients with weak expression of CXCR4 and
VEGFR-3 lived significantly longer with FLO (Figure 5B,
p = 0.011).
Table 1 Patient characteristics
Characteristic All (stained) FLO FLP VEGFR-3 + VEGFR-3 - CXCR4 + CXCR4 -
n n n n n n n
Number 72 38 34 39 30 26 44
Age (years) SD +/− SD +/− SD +/− SD +/− SD +/− SD +/− SD +/−
Mean 59.8 12.04 59.7 12.76 59.9 11.39 62.4 12.33 55.6 10.8 59 12.6 60 11.95
Range 33.1-84.2 33.1-84.2 34.7-78.9 34.7-84.2 33.1-78.9 33.1-84.2 34.7-78.9
Gender % % % % % % %
Male 48 66.7 19 50 29 85.3 26 66.7 19 63.3 19 73.1 28 63.6
Female 24 33.3 19 50 5 14.7 13 33.3 11 36.7 7 26.9 16 36.4
Primary
Cardia 19 26.4 10 26.3 9 27.3 10 25.6 7 24.1 6 23.1 12 27.9
Corpus 27 37.5 15 39.5 12 36.4 14 35.9 12 41.4 12 46.2 15 34.9
Antrum 13 18.1 7 18.4 6 18.2 7 17.9 6 20.7 4 15.4 9 20.9
Esophagus 2 2.8 1 2.6 1 3 2 5.1 0 0 0 0 1 2.3
Stomach 6 8.3 2 5.3 4 12.1 4 10.3 2 6.9 2 7.7 4 9.3
No information 4 5.6 3 7.9 1 3 2 5.1 2 6.9 2 7.7 2 4.7
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Seeking reliable markers to predict chemotherapeutic
efficacy in advanced esophagogastric cancer, tumour tis-
sues from 72 patients from the collective of the FLO vs.
FLP phase III study of the AIO were tested for expres-
sion of VEGFR-3 and CXCR4. Both of these molecules
have recently been associated with aggressive and meta-
static esophagogastric cancer [8,10,12-14,16,20,22,25,26].
As previously described [6,7], no significant difference
between the therapeutic regimes FLO vs FLP was ob-
served in terms of survival of the overall population over
5 years.
In our collective almost half of the specimens showed
a strong positivity for VEGFR-3 (54%), whereas 36% of
all tissue samples proved to be strongly positive for
CXCR4 as assessed by immunohistochemistry. SimilarFigure 1 Immunohistochemistry for VEGFR-3 and CXCR-4 in tumour tis
A. strong positive staining (>5) for VEGFR-3, B. strong positive staining (>5)findings have been reported previously in esophageal
adenocarcinoma [17,33] as well as for adenocarcinoma
of the stomach [11,34]. Taking into consideration that
the majority of the CXCR4 and VEGFR-3 measure-
ments, according to the literature, have been performed
on tumour tissues after curative gastrectomy, we could
expect an increase of the expression of these molecules
in patients who are treated in a palliative setting.
In the present study there was a clear benefit in survival
when the VEGFR-3 negative patients were treated with
oxaliplatin instead of cisplatin. The stronger benefit in this
category of patients was seen in the first 18 months of
treatment. Conversely, patients with strong VEGFR-3 ex-
pression responded better under a cisplatin-containing
regimen. Similar results have been reported by Ni et al.
[35] who showed significantly longer overall survival whensues obtained from patients with esophagogastric adenocarcinoma.
for CXCR4 (black arrows).
Table 2 Distribution of patients’ treatment in relation to
expression of VEGFR-3 or CXCR4
Characteristic FLO FLP
n % n %
VEGFR-3 + 22 56.4 17 43.6
VEGFR-3 - 14 46.7 16 53.3
CXCR4 + 13 50 13 50
CXCR4 - 24 54.5 20 45.5
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cancer and low VEGFR-3 serum levels. The median OS
was 15.4 months whereas in our study it was 22 months.
Ni et al. however, measured only soluble VEGFR-3, thus a
direct comparison between these two studies cannot be
made. Nevertheless, both of these studies indicate high
VEGFR-3 expression is a poor prognostic marker in terms
of survival for patients receiving FLO.
Although the correlation of VEGFR-3 expression and
response to chemotherapy has been the focus of research
in various forms of cancer [36-38], there are only limited
data concerning gastric cancer [39,40]. We have pre-
viously shown the addition of the VEGFR-1-3 inhibitor,
sunitinib to enhance the chemosensitivity of gastric cancer
cell lines in vitro [39]. Our present results demonstrate a
clear benefit of patients with strong VEGFR-3 expression
in favour of FLP specifically when compared with patients
with a low tumour VEGFR-3 expression (Figure 2). In
those patients older than 60 years the benefit of a cisplatin
containing therapy was even greater in the VEGFR-3 posi-
tive group, as no patient in the VEGFR-3 negative sub-
group receiving FLP survived the first year (Figure 4A).
A possible explanation for the enhanced chemo-
sensitivity of VEGFR-3 positive gastric cancer cells to
cisplatin may be deduced by inhibition of the NotchFigure 2 Survival analysis in patients treated with FLO versus FLP in rela
time of 5 years. B. VEGFR-3 positive in observation time of 60 months.pathway. Tamella and colleagues [9] revealed that VEGFR-
3 upregulation in endothelial tip cells, caused by inhibition
of the Notch signalling pathway, played a crucial role in
sprouting angiogenesis in tumours. Since Notch inhibition
has also been connected with the enhanced toxicity of
cisplatin in colorectal cancer lines and nasopharyngeal
adenocarcinoma [41,42], our results may indicate a similar
pathophysiological mechanism for advanced esophagogas-
tric cancer. The reason why oxaliplatin appeared to be less
effective in VEGFR-3 positive patients remains unknown.
However our data are consistent with those of Aleksic
et al. [41], who noticed that several colorectal cancer lines
showed no responsiveness to oxaliplatin, compared with
cisplatin, when Notch signalling was blocked.
When CXCR4 expression levels on tumour tissues
were measured similar results were observed. Patients
with weak CXCR4 expression profited more from FLO
whereas CXCR4 positive patients had a significantly lon-
ger 5 year overall survival under FLP (Figure 3). This
effect could also be clearly seen in patients older than
60 years with strong CXCR4 positivity as they showed a
better response to FLP than the CXCR4 negative ones
(Figure 4B).
To date, the significance of CXCR4 as a potential pre-
dictive marker for chemotherapy in gastric cancer has
been reported only in cellular models [43]. Xie et al.
showed a correlation of CXCR4 mRNA levels in gastric
cancer with docetaxel sensitivity, whereas the blockade of
CXCR4 enhanced docetaxel toxicity. Nevertheless, there
are no data that provide a possible explanation for the
better responsiveness of CXCR4 positive esophagogastric
cancer to cisplatin than to other platinum derives.
It is of great interest in relation to the connection of
extracellular-signal related kinases (ERKs) with the stro-
mal cell-derived factor 1 (SDF-1) mediated pathway. Simi-
lar to VEGFR-3 [41,44,45], the activation of CXCR4 by itstion to the expression of VEGFR-3. A. VEGFR-3 negative in observation
Figure 3 Survival analysis under FLO/FLP treatment in regards of CXCR4 expression in an observation period of 5 years. A. CXCR4
negative. B. CXCR4 positive.
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vation of multiple intracellular domains including ERKs
[46-49]. Since cisplatin relies on ERK activation for bio-
activity in some cells [41,44], in contrast to oxaliplatin
[50], this might explain the chemosensitivity of VEGFR-3
and CXCR4 positive esophagogastric adenocarcinoma to
FLP and not to FLO.
Conclusions
To the best of our knowledge this is the first comparative
study of FLP and FLO in terms of VEGFR-3 and CXCR4
tumour expression. The list below shows the main findings
and conclusions of our trial in accordance to the REMARK
guidelines. The main limitation of our study is its size
(n = 72) and thus, its power is not very high. However, our
results suggest a predictive value of these biomarkers con-
cerning chemotherapy with FLP or FLO in advanced eso-
phagogastric cancer. A trend of longer OS was observed
when CXCR4 and VEGFR-3 positive patients were treated
with FLP, whereas FLO proved to be more effective inFigure 4 Survival analysis under FLP treatment for patients older tha
period of 5 years.CXCR4 and VEGFR-3 negative patients. Further studies
are required in order to investigate the predictive value of
VEGFR-3 and CXCR4 in terms of chemotherapeutic re-
gimes in patients with advanced adenocarcinoma of the
stomach and GEJ.
List of main steps and findings of the current study
according to the REMARK guidelines
Introduction
1. VEGFR-3 and CXCR4 were the examined markers
at this study. The objectives of the current study
were to examine, whether VEGFR-3 and CXCR4
could have a predictive value in patients with
advanced esophagogastric cancer under the
treatment of FLO vs. FLO regime.
Materials and Methods
Patientsn 602. Patients with histologically confirmed locally
advanced or metastatic adenocarcinoma of the
stomach or the esophagogastric junction wereyears. A. VEGF-R3 and B. CXCR4 expression in an observation
Figure 5 Survival analysis under FLO/FLP treatment in an observation period of 5 years. A. VEGF-R3 and CXCR4 positive. B. VEGF-R3 and
CXCR4 negative.
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exclusion criteria have already been described
before [7].
Specimen characteristics and assay methods
3. Paraffin-embedded tissue samples were obtained
from patients with advanced esophagogastric
cancer. The expression of VEGFR-3 and CXCR4
was analyzed by immunohistochemistry.
Evaluation of staining was performed by two
independent, blinded investigators.
Study design
4. This study is a retrospective translational analysis
of a phase III trial in metastatic gastroesophageal
adenocarcinoma. Patients were treated with
fluorouracil, leucovorin plus either oxaliplatin or
cisplatin as described before [7]. Main end point
of the study was overall survival in relation to
VEGFR-3/CXCR4 under palliative chemotherapy.
Statistical analysis methods
5. The staining was evaluated by intensity and the
extent of the stained tumour area. These two
classifications were added together and divided
into the categories negative and positive. All
statistical analyses were done by using SPSS
statistical analysis software. The survival and
univariate analysis were performed by using
Kaplan-Meier method, log rank test, Pearson's
Chi-2 test or Fisher's exact test.
Result
Data
6. The primary tumour location as well as the basic
demographic characteristics of the patients who
participated at the current trial is demonstrated in
Table 1. There was an equal distribution of the
patients in regards of treatment and positivity of
markers.
Analysis and presentation
7. In the survival analysis, patients with strong
expression of CXCR4 on their tumour tissuesprofited more in terms of overall survival under
the treatment of FLP. Patients with negative
VEGFR-3 and CXCR4 expression had a trend
to live longer when treated with FLO. In an
exploratory analysis of patients older than 60 years
at diagnosis, there was a significant benefit in
overall survival for patients with strong VEGFR-3
and CXCR4 expression when treated with FLP.
Discussion
8. CXCR4 positive patients profited in terms of OS
from FLP, whereas FLO proved to be more effective
in CXCR4 and VEGFR-3 negative patients. The
main limitation of our study is its not very high
power, due to the size of the examined tissues
(n = 72). However, our results suggest a predictive
value of these biomarkers concerning chemotherapy
with FLP or FLO in advanced esophagogastric
cancer. Further studies are required in order to
investigate the predictive value of VEGFR-3 and
CXCR4 in terms of chemotherapeutic regimes in
patients with advanced adenocarcinoma of the
stomach and the gastroesophagic junction.
Additional file
Additional file 1: Comparative patient characteristics between the
translational study and the overall phase III trial.
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